Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis

Patients with hematological malignancy and COVID-19 display a high mortality rate. In such patients, immunosuppression due to underlying disease and previous specific treatments impair humoral response, limiting viral clearance. Thus, COVID-19 convalescent plasma (CCP) therapy appears as a promising...

Descripción completa

Detalles Bibliográficos
Autores principales: Hueso, Thomas, Godron, Anne-Sophie, Lanoy, Emilie, Pacanowski, Jérôme, Levi, Laura I., Gras, Emmanuelle, Surgers, Laure, Guemriche, Amina, Meynard, Jean-Luc, Pirenne, France, Idri, Salim, Tiberghien, Pierre, Morel, Pascal, Besson, Caroline, Duléry, Rémy, Lamure, Sylvain, Hermine, Olivier, Gagneux-Brunon, Amandine, Freymond, Nathalie, Grabar, Sophie, Lacombe, Karine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805670/
https://www.ncbi.nlm.nih.gov/pubmed/35105946
http://dx.doi.org/10.1038/s41375-022-01511-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805670/
https://www.ncbi.nlm.nih.gov/pubmed/35105946
http://dx.doi.org/10.1038/s41375-022-01511-6

Ejemplares similares